跨国药企罗氏、默沙东、诺华等近期在中国区高管频繁调整,以应对中国医药市场结构性变化和政策体系深刻变革,如带量采购常态化、支付方式改革和国产创新药崛起。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.